

# Michael Wiese

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5196635/publications.pdf>

Version: 2024-02-01

75  
papers

2,851  
citations

136950

32  
h-index

182427

51  
g-index

82  
all docs

82  
docs citations

82  
times ranked

3163  
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparison of the Usefulness of the MTT, ATP, and Calcein Assays to Predict the Potency of Cytotoxic Agents in Various Human Cancer Cell Lines. <i>Journal of Biomolecular Screening</i> , 2004, 9, 506-515.	2.6	189
2	Structure-activity relationships of flavonoids as inhibitors of breast cancer resistance protein (BCRP). <i>Bioorganic and Medicinal Chemistry</i> , 2011, 19, 2090-2102.	3.0	169
3	Investigation of chalcones and benzochalcones as inhibitors of breast cancer resistance protein. <i>Bioorganic and Medicinal Chemistry</i> , 2012, 20, 346-355.	3.0	97
4	Combined Pharmacophore Modeling, Docking, and 3D QSAR Studies of ABCB1 and ABCC1 Transporter Inhibitors. <i>ChemMedChem</i> , 2009, 4, 1883-1896.	3.2	89
5	Investigation of quinazolines as inhibitors of breast cancer resistance protein (ABCG2). <i>Bioorganic and Medicinal Chemistry</i> , 2013, 21, 7858-7873.	3.0	84
6	Synthesis and biological evaluation of flavones and benzoflavones as inhibitors of BCRP/ABCG2. <i>European Journal of Medicinal Chemistry</i> , 2013, 67, 115-126.	5.5	83
7	Structure-activity relationships of new inhibitors of breast cancer resistance protein (ABCG2). <i>Bioorganic and Medicinal Chemistry</i> , 2008, 16, 8224-8236.	3.0	82
8	Design, synthesis and biological evaluation of thiosemicarbazones, hydrazinobenzothiazoles and arylhydrazones as anticancer agents with a potential to overcome multidrug resistance. <i>European Journal of Medicinal Chemistry</i> , 2016, 117, 335-354.	5.5	79
9	Specific Inhibitors of the Breast Cancer Resistance Protein (BCRP). <i>ChemMedChem</i> , 2010, 5, 1498-1505.	3.2	73
10	Tyrosine Kinase Inhibitors Influence ABCG2 Expression in EGFR-Positive MDCK BCRP Cells via the PI3K/Akt Signaling Pathway. <i>ChemMedChem</i> , 2012, 7, 650-662.	3.2	71
11	Identification of Putative Binding Sites of P-glycoprotein Based on its Homology Model. <i>ChemMedChem</i> , 2008, 3, 280-295.	3.2	70
12	HM30181 Derivatives as Novel Potent and Selective Inhibitors of the Breast Cancer Resistance Protein (BCRP/ABCG2). <i>Journal of Medicinal Chemistry</i> , 2015, 58, 3910-3921.	6.4	69
13	In vitro and in vivo evaluation of WK-X-34, a novel inhibitor of P-glycoprotein and BCRP, using radio imaging techniques. <i>International Journal of Cancer</i> , 2006, 119, 414-422.	5.1	67
14	New functional assay of P-glycoprotein activity using Hoechst 33342. <i>Bioorganic and Medicinal Chemistry</i> , 2007, 15, 7470-7479.	3.0	60
15	Functional assay and structure-activity relationships of new third-generation P-glycoprotein inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2008, 16, 2448-2462.	3.0	60
16	Synthesis and Investigation of Tetrahydro- $\beta$ -carboline Derivatives as Inhibitors of the Breast Cancer Resistance Protein (ABCG2). <i>Journal of Medicinal Chemistry</i> , 2016, 59, 6121-6135.	6.4	57
17	4-Substituted-2-phenylquinazolines as inhibitors of BCRP. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 6766-6769.	2.2	54
18	The combination of quinazoline and chalcone moieties leads to novel potent heterodimeric modulators of breast cancer resistance protein (BCRP/ABCG2). <i>European Journal of Medicinal Chemistry</i> , 2016, 117, 212-229.	5.5	52

#	ARTICLE	IF	CITATIONS
19	9-Deazapurines as Broad-Spectrum Inhibitors of the ABC Transport Proteins P-Glycoprotein, Multidrug Resistance-Associated Protein 1, and Breast Cancer Resistance Protein. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 8758-8780.	6.4	52
20	Synthesis and Biological Evaluation of 4-Anilino-quinazolines and -quinolines as Inhibitors of Breast Cancer Resistance Protein (ABCG2). <i>Journal of Medicinal Chemistry</i> , 2016, 59, 5449-5461.	6.4	51
21	Synthesis and biological evaluation of a small molecule library of 3rd generation multidrug resistance modulators. <i>Bioorganic and Medicinal Chemistry</i> , 2009, 17, 2524-2535.	3.0	50
22	Small molecule inhibitors of multidrug resistance-associated protein 1 and related processes: A historic approach and recent advances. <i>Medicinal Research Reviews</i> , 2019, 39, 176-264.	10.5	50
23	Total Synthesis of Natural and Non-Natural <sup>5,6</sup> <sup>12,13</sup> -Jatrophane Diterpenes and Their Evaluation as MDR Modulators. <i>Journal of Organic Chemistry</i> , 2011, 76, 512-522.	3.2	49
24	Structure-activity relationships of a series of tariquidar analogs as multidrug resistance modulators. <i>Bioorganic and Medicinal Chemistry</i> , 2006, 14, 1588-1598.	3.0	47
25	Pyrrolopyrimidine Derivatives as Novel Inhibitors of Multidrug Resistance-Associated Protein 1 (MRP1.) <i>Tj ETQq1 1 0.784314 rgBT /Overl</i>	6.4	44
26	4-Anilino-2-pyridylquinazolines and -pyrimidines as Highly Potent and Nontoxic Inhibitors of Breast Cancer Resistance Protein (ABCG2). <i>Journal of Medicinal Chemistry</i> , 2017, 60, 4474-4495.	6.4	43
27	Novel chalcone and flavone derivatives as selective and dual inhibitors of the transport proteins ABCB1 and ABCG2. <i>European Journal of Medicinal Chemistry</i> , 2019, 164, 193-213.	5.5	39
28	Synthesis and biological investigation of 2,4-substituted quinazolines as highly potent inhibitors of breast cancer resistance protein (ABCG2). <i>European Journal of Medicinal Chemistry</i> , 2017, 139, 587-611.	5.5	38
29	2,4,6-Substituted Quinazolines with Extraordinary Inhibitory Potency toward ABCG2. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 7952-7976.	6.4	37
30	Protein Contacts and Ligand Binding in the Inward-Facing Model of Human P-Glycoprotein. <i>ChemMedChem</i> , 2013, 8, 748-762.	3.2	35
31	New Inhibitors of Breast Cancer Resistance Protein (ABCG2) Containing a 2,4-Disubstituted Pyridopyrimidine Scaffold. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 3389-3408.	6.4	35
32	Activators of P-Glycoprotein: Structure-Activity Relationships and Investigation of their Mode of Action. <i>ChemMedChem</i> , 2009, 4, 1897-1911.	3.2	33
33	Structure-Activity Relationships of Tariquidar Analogs as Multidrug Resistance Modulators. <i>AAPS Journal</i> , 2009, 11, 435-44.	4.4	32
34	Synthesis and Quantitative Structure-Activity Relationships of Selective BCRP Inhibitors. <i>ChemMedChem</i> , 2013, 8, 125-135.	3.2	30
35	Characterization of 3-methoxy flavones for their interaction with ABCG2 as suggested by ATPase activity. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2014, 1838, 2929-2938.	2.6	30
36	Molecular Recognition of Agonists and Antagonists by the Nucleotide-Activated G Protein-Coupled P2Y <sub>2</sub> Receptor. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 8425-8440.	6.4	27

#	ARTICLE	IF	CITATIONS
37	Synthesis and biological evaluation of quinazoline derivatives – A SAR study of novel inhibitors of ABCG2. <i>European Journal of Medicinal Chemistry</i> , 2019, 161, 506-525.	5.5	27
38	Novel lead for potent inhibitors of breast cancer resistance protein (BCRP). <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 180-183.	2.2	25
39	Interactions of the Multidrug Resistance Modulators Tariquidar and Elacridar and their Analogues with P-glycoprotein. <i>ChemMedChem</i> , 2013, 8, 1701-1713.	3.2	25
40	Scaffold Identification of a New Class of Potent and Selective BCRP Inhibitors. <i>ChemMedChem</i> , 2015, 10, 742-751.	3.2	25
41	Synthesis and characterization of the anticancer and metal binding properties of novel pyrimidinylhydrazone derivatives. <i>Journal of Inorganic Biochemistry</i> , 2015, 144, 18-30.	3.5	25
42	Aromatic 2-(Thio)ureidocarboxylic Acids As a New Family of Modulators of Multidrug Resistance-Associated Protein 1: Synthesis, Biological Evaluation, and Structure-Activity Relationships. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 4586-4595.	6.4	24
43	Identification of Thienopyrimidine Scaffold as an Inhibitor of the ABC Transport Protein ABCC1 (MRP1) and Related Transporters Using a Combined Virtual Screening Approach. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 4383-4400.	6.4	24
44	The Role of small-molecule ABC transport protein modulators: From inhibition to activation – a case study of multidrug resistance-associated protein 1 (ABCC1). <i>Medicinal Research Reviews</i> , 2019, 39, 2031-2081.	10.5	24
45	Novel tetrahydroisoquinolin-ethyl-phenylamine based multidrug resistance inhibitors with broad-spectrum modulating properties. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 59, 61-69.	2.3	23
46	Gene expression signatures of angiocidin and darapladib treatment connect to therapy options in cervical cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013, 139, 259-267.	2.5	23
47	8-Substituted 1,3-dimethyltetrahydropyrazino[2,1-f]purinediones: Water-soluble adenosine receptor antagonists and monoamine oxidase B inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2016, 24, 5462-5480.	3.0	23
48	Pyrolopyrimidine derivatives and purine analogs as novel activators of Multidrug Resistance-associated Protein 1 (MRP1, ABCC1). <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2017, 1859, 69-79.	2.6	23
49	Structure activity relationships, multidrug resistance reversal and selectivity of heteroarylphenyl ABCG2 inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2018, 146, 483-500.	5.5	23
50	A 4-aminobenzoic acid derivative as novel lead for selective inhibitors of multidrug resistance-associated proteins. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 4761-4763.	2.2	21
51	Superior Pyrimidine Derivatives as Selective ABCG2 Inhibitors and Broad-Spectrum ABCB1, ABCC1, and ABCG2 Antagonists. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 10412-10432.	6.4	21
52	Evaluation of dual P-gp-BCRP inhibitors as nanoparticle formulation. <i>European Journal of Pharmaceutical Sciences</i> , 2015, 77, 1-8.	4.0	18
53	C@PA: Computer-Aided Pattern Analysis to Predict Multitarget ABC Transporter Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 3350-3366.	6.4	18
54	Analogues of a 4-aminothieno[2,3-d]pyrimidine lead (QB13) as modulators of P-glycoprotein substrate specificity. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 6102-6105.	2.2	17

#	ARTICLE	IF	CITATIONS
55	Rational drug design of 6-substituted 4-anilino-2-phenylpyrimidines for exploration of novel ABCG2 binding site. <i>European Journal of Medicinal Chemistry</i> , 2021, 212, 113045.	5.5	17
56	Phenyltetrazolyl-phenylamides: Substituent impact on modulation capability and selectivity toward the efflux protein ABCG2 and investigation of interaction with the transporter. <i>European Journal of Medicinal Chemistry</i> , 2016, 124, 881-895.	5.5	16
57	Acryloylphenylcarboxamides: A New Class of Breast Cancer Resistance Protein (ABCG2) Modulators. <i>ChemMedChem</i> , 2016, 11, 2422-2435.	3.2	15
58	BCRP/ABCG2 inhibitors: a patent review (2009-present). <i>Expert Opinion on Therapeutic Patents</i> , 2015, 25, 1229-37.	5.0	15
59	Association between acquired resistance to PLX4032 (vemurafenib) and ATP-binding cassette transporter expression. <i>BMC Research Notes</i> , 2014, 7, 710.	1.4	13
60	Design of inhibitors of BCRP/ABCG2. <i>Future Medicinal Chemistry</i> , 2015, 7, 1521-1527.	2.3	13
61	Optimization of Acryloylphenylcarboxamides as Inhibitors of ABCG2 and Comparison with Acryloylphenylcarboxylates. <i>ChemMedChem</i> , 2016, 11, 2547-2558.	3.2	13
62	The Pyrazolo[3,4-d]pyrimidine Derivative, SCO-201, Reverses Multidrug Resistance Mediated by ABCG2/BCRP. <i>Cells</i> , 2020, 9, 613.	4.1	13
63	Structural feature-driven pattern analysis for multitarget modulator landscapes. <i>Bioinformatics</i> , 2022, 38, 1385-1392.	4.1	13
64	Scaffold fragmentation and substructure hopping reveal potential, robustness, and limits of computer-aided pattern analysis (C@PA). <i>Computational and Structural Biotechnology Journal</i> , 2021, 19, 3269-3283.	4.1	12
65	ABCG2 impairs the activity of the aurora kinase inhibitor tozasertib but not of alisertib. <i>BMC Research Notes</i> , 2015, 8, 484.	1.4	10
66	Halogenation-Guided Chemical Screening Provides Insight into Tjipanazole Biosynthesis by the Cyanobacterium <i>Fischerella ambigua</i> . <i>ChemBioChem</i> , 2020, 21, 2170-2177.	2.6	9
67	Synthesis and biological assessment of new pyrimidopyrimidines as inhibitors of breast cancer resistance protein (ABCG2). <i>Bioorganic Chemistry</i> , 2021, 116, 105326.	4.1	9
68	Probing Substituents in the 1- and 3-Position: Tetrahydropyrazino-Annulated Water-Soluble Xanthine Derivatives as Multi-Target Drugs With Potent Adenosine Receptor Antagonistic Activity. <i>Frontiers in Chemistry</i> , 2018, 6, 206.	3.6	8
69	Synthesis of Homoverrucosanoid-Derived Esters and Evaluation as MDR Modulators. <i>Journal of Organic Chemistry</i> , 2017, 82, 10504-10522.	3.2	7
70	Molecular Modeling of P-Glycoprotein and Related Drugs. <i>Medicinal Chemistry Research</i> , 2005, 14, 106-117.	2.4	6
71	Quality Visualization of Microarray Datasets Using Circos. <i>Microarrays (Basel, Switzerland)</i> , 2012, 1, 84-94.	1.4	3
72	Recombinant Synthesis of Human ABCG2 Expressed in the Yeast <i>Saccharomyces cerevisiae</i> : an Experimental Methodological Study. <i>Protein Journal</i> , 2011, 30, 201-211.	1.6	2

#	ARTICLE	IF	CITATIONS
73	A Microarray Tool Provides Pathway and GO Term Analysis. <i>Molecular Informatics</i> , 2011, 30, 918-921.	2.5	2
74	Feature extraction via composite scoring and voting in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012, 135, 307-318.	2.5	2
75	HAGE, the helicase antigen as a biomarker for breast cancer prognosis (WO2013144616). <i>Expert Opinion on Therapeutic Patents</i> , 2014, 24, 723-725.	5.0	2